High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer

Strahlentherapie und Onkologie

Volumn 186, Issue 12, 2010, Pages 687-692

  Ghadjar, Pirus ^a   Gwerder, Nicole ^a   Manser, Peter ^a   Vock, Jacqueline ^a   Madlung, Axel ^a   Mini, Roberto ^a   Aebersold, Daniel M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Daily image guidance; High dose; IMRT; Prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN ANTAGONIST;

AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSIMETRY; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAZARD RATIO; HEMATURIA; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREDICTOR VARIABLE; PROCTALGIA; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RADIATION DOSE; RADIATION HAZARD; RATING SCALE; RECTUM HEMORRHAGE; SCORING SYSTEM; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; TRANSURETHRAL RESECTION OF PROSTATE; UROGENITAL SYSTEM;

EID: 79951679049     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2180-8     Document Type: Article

References (31)

1. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multi center dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;72:980-8.
2. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008;71:330-7.
3. Cox DR, Oakes D. Analysis of survival data. London, United Kingdom: Chapman and Hall, 1984;110-20.
4. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standarddose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87. (Pubitemid 46805903)
5. D?Amico AV, Whittington R, Malkowitcz SB, et al. Biochemical outcome after radical prostatectomy external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280: 969-74. (Pubitemid 28445094)
6. Dolezel M, Odrazka K, Vaculikova M, et al. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost. Strahlenther Onkol 2009;186:197-202.
7. Fonteyne V, Villeirs G, Lumen N, et al. Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol 2009;92:42-7.
8. Ghadjar P, Vock J, Vetterli D et al. Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiat Oncol 2008;3:35.
9. Goldner G, Dimopoulos J, Kirisits C, et al. Moderate dose escalation in threedimensional conformal localized prostate cancer radiotherapy. Strahlenther Onkol 2009;7:438-45.
10. Guckenberger M, Flentje M. Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: a review and future perspectives. Strahlenther Onkol 2007;183:57-62.
11. Harris EK, Albert A. Survivorship analysis for clinical studies. New York, NY: Marcel Dekker, 1991;5-125.
12. Heemsbergen WD, Peeters STH, Koper PCM, et al. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 2006;66:3-10. (Pubitemid 44175664)
13. Kalz J, Sterzing F, Schubert K, et al. Dosimetric comparison of image guidance by megavoltage computed tomography versus bone alignment for prostate cancer radiotherapy. Strahlenther Onkol 2009;185:241-7.
14. Kessler TM, Burkhard FC, Studer UE. Nerve-sparing open radical retropubic prostatectomy. Eur Urol 2007;51:90-7. (Pubitemid 44821540)
15. Kuban DA, Tucker SL, Dong L, et al. Long-term results of of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. (Pubitemid 350251041)
16. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20:3376-85.
17. Lawton CA, Bae K, Pilepich M, et al. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: Analysis of Radiation Therapy Oncology Group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys 2008;70:437-41.
18. Leibel SA, Fuks Z, Zelefsky MJ, et al. Technological advances in externalbeam radiation therapy for the treatment of localized prostate cancer. Semin Radiat Oncol 2003;30:596-615. (Pubitemid 37296786)
19. Matzinger O, Duclos F, van den Bergh A, et al. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009;45:2825-34.
20. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34. (Pubitemid 40340897)
21. Pinkawa M, Pursch-Lee M, Asadpour B, et al. Image-guided radiotherapy for prostate cancer. Strahlenther Onkol 2008;12:679-85.
22. Polat B, Guenther I, Wilbert J. Intra-fractional uncertainties in image- guided intensity-modulated radiotherapy (IMRT) of prostate cancer. Strahlenther Onkol 2008;184:668-73.
23. Roach 3rd M. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:1923-4.
24. Roach 3rd M, Hanks G, Thames Jr. H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
25. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23:1192-9. (Pubitemid 46202276)
26. Schultheiss TE, Hanks GE, Hunt MA, et al. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys 2002;54:442-9.
27. Sobin LH, Wittekind CH. The prostate. In: TNM classification of malignant tumors. New York: Wiley-Liss, 2002;184-7.
28. Treutwein M, Hipp M, Kobl O, et al. IMRT of prostate cancer. Strahlenther Onkol 2009;185:379-83.
29. Vetterli D, Thalmann S, Behrensmeier Fet al. Daily organ tracking in intensity- modulated radiotherapy of prostate cancer using an electronic portal imaging device with a dose saving acquisition mode. Radiother Oncol 2006;79:101-8.
30. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensitymodulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124-9. (Pubitemid 351296130)
31. Zietman Al, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9. (Pubitemid 41352111)